Glycation potentiates neurodegeneration in models of Huntington's disease

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Vicente Miranda, Hugo ^a,b   Gomes, Marcos António ^b   Branco Santos, Joana ^c,d   Breda, Carlo ^c   Lázaro, Diana F ^e   Lopes, Luísa Vaqueiro ^b   Herrera, Federico ^d   Giorgini, Flaviano ^c   Outeiro, Tiago Fleming ^a,e,f  

^a NOVA MEDICAL SCHOOL   (Portugal)

^b INSTITUTO DE MEDICINA MOLECULAR   (Portugal)

^c UNIVERSITY OF LEICESTER   (United Kingdom)

^d INSTITUTO DE TECNOLOGIA QUÍMICA E BIOLÓGICA   (Portugal)

^e UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^f MAX PLANCK INSTITUTE OF EXPERIMENTAL MEDICINE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GREEN FLUORESCENT PROTEIN; HTT PROTEIN, HUMAN; HUNTINGTIN; NERVE PROTEIN; NUCLEAR PROTEIN;

ANIMAL; AUTOPHAGY; CELL LINE; DEGENERATIVE DISEASE; DISEASE MODEL; DROSOPHILA; EXON; FEMALE; GENE SILENCING; GENETICS; HUMAN; HUNTINGTON CHOREA; MALE; METABOLISM; MUTATION; NERVE CELL; SACCHAROMYCES CEREVISIAE; TREATMENT OUTCOME;

ANIMALS; AUTOPHAGY; CELL LINE; DISEASE MODELS, ANIMAL; DROSOPHILA; EXONS; FEMALE; GENE SILENCING; GREEN FLUORESCENT PROTEINS; HUMANS; HUNTINGTIN PROTEIN; HUNTINGTON DISEASE; MALE; MUTATION; NERVE TISSUE PROTEINS; NEURODEGENERATIVE DISEASES; NEURONS; NUCLEAR PROTEINS; SACCHAROMYCES CEREVISIAE; TREATMENT OUTCOME;

EID: 84995899643     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep36798     Document Type: Article

References (64)

1. MacDonald, M. E. et al. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 72, 971-983, doi: http://dx. doi. org/10. 1016/0092-8674(93)90585-E (1993).
2. Labbadia, J., Morimoto, R. I. Huntington's disease: underlying molecular mechanisms and emerging concepts. Trends in biochemical sciences 38, 378-385, doi: 10. 1016/j. tibs. 2013. 05. 003 (2013).
3. Munoz-Sanjuan, I., Bates, G. P. The importance of integrating basic and clinical research toward the development of new therapies for Huntington disease. The Journal of clinical investigation 121, 476-483, doi: 10. 1172/JCI45364 (2011).
4. Walker, F. O. Huntington's disease. Lancet 369, 218-228, doi: 10. 1016/S0140-6736(07)60111-1 (2007).
5. Li, S. H., Li, X. J. Aggregation of N-terminal huntingtin is dependent on the length of its glutamine repeats. Human molecular genetics 7, 777-782 (1998).
6. Javed, S., Petropoulos, I. N., Alam, U., Malik, R. A. Treatment of painful diabetic neuropathy. Ther Adv Chronic Dis 6, 15-28, doi: 10. 1177/2040622314552071 (2015).
7. Schreiber, A. K., Nones, C. F., Reis, R. C., Chichorro, J. G., Cunha, J. M. Diabetic neuropathic pain: Physiopathology and treatment. World J Diabetes 6, 432-444, doi: 10. 4239/wjd. v6. i3. 432 (2015).
8. Vicente Miranda, H., El-Agnaf, O. M., Outeiro, T. F. Glycation in Parkinson's disease and Alzheimer's disease. Mov Disord, doi: 10. 1002/mds. 26566 (2016).
9. Vicente Miranda, H., Outeiro, T. F. The sour side of neurodegenerative disorders: the effects of protein glycation. The Journal of pathology 221, 13-25, doi: 10. 1002/path. 2682 (2010).
10. Richard, J. P. Kinetic parameters for the elimination reaction catalyzed by triosephosphate isomerase and an estimation of the reaction's physiological significance. Biochemistry 30, 4581-4585 (1991).
11. Guix, F. X. et al. Amyloid-dependent triosephosphate isomerase nitrotyrosination induces glycation and tau fibrillation. Brain 132, 1335-1345, doi: 10. 1093/brain/awp023 (2009).
12. Orosz, F., Olah, J., Ovadi, J. Triosephosphate isomerase deficiency: new insights into an enigmatic disease. Biochim Biophys Acta 1792, 1168-1174, doi: 10. 1016/j. bbadis. 2009. 09. 012 (2009).
13. Vicente Miranda, H. et al. Heat-mediated enrichment of alpha-synuclein from cells and tissue for assessing post-translational modifications. Journal of neurochemistry 126, 673-684, doi: 10. 1111/jnc. 12251 (2013).
14. Gomes, R. A. et al. Protein glycation in Saccharomyces cerevisiae. Argpyrimidine formation and methylglyoxal catabolism. FEBS J 272, 4521-4531, doi: 10. 1111/j. 1742-4658. 2005. 04872. x (2005).
15. Ciriacy, M., Breitenbach, I. Physiological effects of seven different blocks in glycolysis in Saccharomyces cerevisiae. J Bacteriol 139, 152-160 (1979).
16. Hollan, S. et al. Hereditary triosephosphate isomerase (TPI) deficiency: two severely affected brothers one with and one without neurological symptoms. Hum Genet 92, 486-490 (1993).
17. Phillips, S. A., Thornalley, P. J. The formation of methylglyoxal from triose phosphates. Investigation using a specific assay for methylglyoxal. Eur J Biochem 212, 101-105 (1993).
18. Ahmed, N. et al. Increased formation of methylglyoxal and protein glycation, oxidation and nitrosation in triosephosphate isomerase deficiency. Biochim Biophys Acta 1639, 121-132 (2003).
19. Correia, K. et al. The Genetic Modifiers of Motor OnsetAge (GeM MOA) Website: Genome-wide Association Analysis for Genetic Modifiers of Huntington's Disease. Journal of Huntington's disease 4, 279-284, doi: 10. 3233/JHD-150169 (2015).
20. Lee, J.-M. et al. Identification of Genetic Factors that Modify Clinical Onset of Huntington's Disease. Cell 162, 516-526, doi: http://dx. doi. org/10. 1016/j. cell. 2015. 07. 003 (2015).
21. Mo, C., Hannan, A. J., Renoir, T. Environmental factors as modulators of neurodegeneration: insights from gene-environment interactions in Huntington's disease. Neuroscience and biobehavioral reviews 52, 178-192, doi: 10. 1016/j. neubiorev. 2015. 03. 003 (2015).
22. van Dellen, A., Hannan, A. J. Genetic and environmental factors in the pathogenesis of Huntington's disease. Neurogenetics 5, 9-17, doi: 10. 1007/s10048-003-0169-5 (2004).
23. Ma, L., Nicholson, L. F. Expression of the receptor for advanced glycation end products in Huntington's disease caudate nucleus. Brain research 1018, 10-17, doi: 10. 1016/j. brainres. 2004. 05. 052 (2004).
24. Anzilotti, S. et al. Immunohistochemical localization of receptor for advanced glycation end (RAGE) products in the R6/2 mouse model of Huntington's disease. Brain Res Bull 87, 350-358, doi: 10. 1016/j. brainresbull. 2011. 01. 009 (2012).
25. Sajjad, M. U. et al. DJ-1 modulates aggregation and pathogenesis in models of Huntington's disease. Human molecular genetics 23, 755-766, doi: 10. 1093/hmg/ddt466 (2014).
26. Krobitsch, S., Lindquist, S. Aggregation of huntingtin in yeast varies with the length of the polyglutamine expansion and the expression of chaperone proteins. Proceedings of the National Academy of Sciences of the United States of America 97, 1589-1594 (2000).
27. Duennwald, M. L., Jagadish, S., Muchowski, P. J., Lindquist, S. Flanking sequences profoundly alter polyglutamine toxicity in yeast. Proceedings of the National Academy of Sciences of the United States of America 103, 11045-11050, doi: 10. 1073/pnas. 0604547103 (2006).
28. Meriin, A. B. et al. Aggregation of expanded polyglutamine domain in yeast leads to defects in endocytosis. Molecular and cellular biology 23, 7554-7565 (2003).
29. Herrera, F., Tenreiro, S., Miller-Fleming, L., Outeiro, T. F. Visualization of cell-to-cell transmission of mutant huntingtin oligomers. PLoS Curr 3, RRN1210, doi: 10. 1371/currents. RRN1210 (2011).
30. Chang, T. J. et al. Glucagon-like peptide-1 prevents methylglyoxal-induced apoptosis of beta cells through improving mitochondrial function and suppressing prolonged AMPK activation. Sci Rep 6, 23403, doi: 10. 1038/srep23403 (2016).
31. Hansen, F. et al. Methylglyoxal and carboxyethyllysine reduce glutamate uptake and S100B secretion in the hippocampus independently of RAGE activation. Amino Acids 48, 375-385, doi: 10. 1007/s00726-015-2091-1 (2016).
32. Nass, N. et al. Differential response to alpha-oxoaldehydes in tamoxifen resistant MCF-7 breast cancer cells. PLoS One 9, e101473, doi: 10. 1371/journal. pone. 0101473 (2014).
33. Klionsky, D. J. et al. Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy 12, 1-222, doi: 10. 1080/15548627. 2015. 1100356 (2016).
34. Bence, N. F., Sampat, R. M., Kopito, R. R. Impairment of the ubiquitin-proteasome system by protein aggregation. Science 292, 1552-1555, doi: 10. 1126/science. 292. 5521. 1552 (2001).
35. Steffan, J. S. et al. Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila. Nature 413, 739-743, doi: 10. 1038/35099568 (2001).
36. Green, E. W., Giorgini, F. Choosing and using Drosophila models to characterize modifiers of Huntington's disease. Biochem Soc Trans 40, 739-745, doi: 10. 1042/BST20120072 (2012).
37. Mason, R. P. et al. Glutathione peroxidase activity is neuroprotective in models of Huntington's disease. Nature genetics 45, 1249-1254, doi: 10. 1038/ng. 2732 (2013).
38. Wild, E. J., Tabrizi, S. J. Targets for future clinical trials in Huntington's disease: what's in the pipeline Mov Disord 29, 1434-1445, doi: 10. 1002/mds. 26007 (2014).
39. Ehrnhoefer, D. E., Sutton, L., Hayden, M. R. Small changes, big impact: posttranslational modifications and function of huntingtin in Huntington disease. The Neuroscientist: a review journal bringing neurobiology, neurology and psychiatry 17, 475-492, doi: 10. 1177/1073858410390378 (2011).
40. Krainc, D. Huntington's disease: tagged for clearance. Nature medicine 16, 32-33, doi: 10. 1038/nm0110-32 (2010).
41. Saudou, F., Humbert, S. The Biology of Huntingtin. Neuron 89, 910-926, doi: 10. 1016/j. neuron. 2016. 02. 003 (2016).
42. Gu, X. et al. Serines 13 and 16 are critical determinants of full-length human mutant huntingtin induced disease pathogenesis in HD mice. Neuron 64, 828-840, doi: 10. 1016/j. neuron. 2009. 11. 020 (2009).
43. Thompson, L. M. et al. IKK phosphorylates Huntingtin and targets it for degradation by the proteasome and lysosome. The Journal of cell biology 187, 1083-1099, doi: 10. 1083/jcb. 200909067 (2009).
44. Jeong, H. et al. Acetylation targets mutant huntingtin to autophagosomes for degradation. Cell 137, 60-72, doi: 10. 1016/j. cell. 2009. 03. 018 (2009).
45. Wang, Y., Lin, F., Qin, Z. H. The role of post-translational modifications of huntingtin in the pathogenesis of Huntington's disease. Neuroscience bulletin 26, 153-162, doi: 10. 1007/s12264-010-1118-6 (2010).
46. Nixon, R. A. The role of autophagy in neurodegenerative disease. Nature medicine 19, 983-997, doi: 10. 1038/nm. 3232 (2013).
47. Yamamoto, A., Cremona, M. L., Rothman, J. E. Autophagy-mediated clearance of huntingtin aggregates triggered by the insulinsignaling pathway. The Journal of cell biology 172, 719-731, doi: 10. 1083/jcb. 200510065 (2006).
48. Li, X. H. et al. Glycation exacerbates the neuronal toxicity of beta-amyloid. Cell death & disease 4, e673, doi: 10. 1038/cddis. 2013. 180 (2013).
49. Ma, T. C. et al. Metformin therapy in a transgenic mouse model of Huntington's disease. Neuroscience letters 411, 98-103, doi: 10. 1016/j. neulet. 2006. 10. 039 (2007).
50. Martin, B. et al. Exendin-4 improves glycemic control, ameliorates brain and pancreatic pathologies, and extends survival in a mouse model of Huntington's disease. Diabetes 58, 318-328, doi: 10. 2337/db08-0799 (2009).
51. Farrer, L. A. Diabetes mellitus in Huntington disease. Clinical genetics 27, 62-67 (1985).
52. Podolsky, S., Leopold, N. A., Sax, D. S. Increased frequency of diabetes mellitus in patients with Huntington's chorea. Lancet 1, 1356-1358 (1972).
53. Hurlbert, M. S. et al. Mice transgenic for an expanded CAG repeat in the Huntington's disease gene develop diabetes. Diabetes 48, 649-651 (1999).
54. Jenkins, B. G. et al. Nonlinear decrease over time in N-acetyl aspartate levels in the absence of neuronal loss and increases in glutamine and glucose in transgenic Huntington's disease mice. Journal of neurochemistry 74, 2108-2119 (2000).
55. Andreassen, O. A. et al. Huntington's disease of the endocrine pancreas: insulin deficiency and diabetes mellitus due to impaired insulin gene expression. Neurobiology of disease 11, 410-424 (2002).
56. Bjorkqvist, M. et al. The R6/2 transgenic mouse model of Huntington's disease develops diabetes due to deficient beta-cell mass and exocytosis. Human molecular genetics 14, 565-574, doi: 10. 1093/hmg/ddi053 (2005).
57. Schonberger, S. J., Jezdic, D., Faull, R. L., Cooper, G. J. Proteomic analysis of the human brain in Huntington's Disease indicates pathogenesis by molecular processes linked to other neurodegenerative diseases and to type-2 diabetes. Journal of Huntington's disease 2, 89-99, doi: 10. 3233/JHD-120044 (2013).
58. Harris, H., Rubinsztein, D. C. Control of autophagy as a therapy for neurodegenerative disease. Nature reviews. Neurology 8, 108-117, doi: 10. 1038/nrneurol. 2011. 200 (2012).
59. Puyal, J., Ginet, V., Grishchuk, Y., Truttmann, A. C., Clarke, P. G. Neuronal autophagy as a mediator of life and death: contrasting roles in chronic neurodegenerative and acute neural disorders. The Neuroscientist: a review journal bringing neurobiology, neurology and psychiatry 18, 224-236, doi: 10. 1177/1073858411404948 (2012).
60. Lee, J. Y. et al. Human DJ-1 and its homologs are novel glyoxalases. Human molecular genetics 21, 3215-3225, doi: 10. 1093/hmg/dds155 (2012).
61. Richarme, G. et al. Parkinsonism-associated protein DJ-1/Park7 is a major protein deglycase that repairs methylglyoxal-and glyoxal-glycated cysteine, arginine, and lysine residues. The Journal of biological chemistry 290, 1885-1897, doi: 10. 1074/jbc. M114. 597815 (2015).
62. Herrera, F., Outeiro, T. F. Alpha-Synuclein modifies huntingtin aggregation in living cells. FEBS letters 586, 7-12, doi: 10. 1016/j. febslet. 2011. 11. 019 (2012).
63. Guerreiro, P. S. et al. LRRK2 interactions with alpha-synuclein in Parkinson's disease brains and in cell models. J Mol Med (Berl) 91, 513-522, doi: 10. 1007/s00109-012-0984-y (2013).
64. Breda, C. et al. Tryptophan-2, 3-dioxygenase (TDO) inhibition ameliorates neurodegeneration by modulation of kynurenine pathway metabolites. Proceedings of the National Academy of Sciences of the United States of America 113, 5435-5440, doi: 10. 1073/pnas. 1604453113 (2016).